CG Oncology Promising Early Data for Bladder Cancer at American Urological Association

CG Oncology (NASDAQ: CGON) has announced significant results for cretostimogene grenadenorepvec in treating bladder cancer at the 2025 American Urological Association Annual Meeting. The Phase 3 BOND-003 Cohort C study showed impressive durability with a 24-month complete response rate of 42.3% in high-risk non-muscle invasive bladder cancer (NMIBC) patients.

Key findings include:75.5% complete response rate at any time
97.3% of patients remained free from progression to muscle invasive disease at 24 months
91.6% of responders remained cystectomy-free at 24 months
Median duration of response of 28 months (ongoing)



Additionally, Cohort P demonstrated 90.5% high-grade recurrence-free survival at 3 and 9 months. The treatment showed excellent safety with no Grade 3 or greater treatment-related adverse events reported.

https://www.stocktitan.net/news/CGON/cg-oncology-announces-best-in-disease-durability-data-in-bond-003-mlx6lxahtm91.html